Rare Disease Treatment Unexpectedly Rejected by the FDA

September 4, 2019

Rare Disease Treatment Unexpectedly Rejected by the FDA

In a surprise decision, the U.S. Food and Drug Administration has rejected Sarepta’s experimental exon-skipping drug Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy, citing risks of both infection and kidney toxicity. Yourway is dedicated to supporting clinical trials for advanced therapies for orphan diseases.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?